Novo Nordisk will significantly lower the list prices for its blockbuster GLP-1 medications, Ozempic, Rybelsus, and Wegovy, effective January 1, 2027. The new list price will be $675 for a one-month supply, a substantial decrease from the current over $1,000 price point, with Wegovy injections and pills previously topping $1,349.
These price adjustments are strategically targeted at consumers with insurance plans that tie coverage to the drug's list price, aiming to improve affordability for those facing coinsurance or high-deductible plans. Novo Nordisk officials state the move responds to calls for lower list prices from policymakers and patients.
The price cuts arrive as Novo Nordisk faces intensifying competition, particularly from Eli Lilly's Zepbound. Recent study results comparing Novo's next-generation obesity drug, CagriSema, to Eli Lilly's Zepbound showed less significant weight loss for CagriSema participants, leading to a notable drop in Novo Nordisk's stock.
While cash-paying customers have seen previous price reductions, the new list price cuts are designed to impact the broader insured market. Novo's decision to announce these changes over 10 months in advance aims to allow stakeholders like employers and health insurers to adjust their benefit plans accordingly, focusing on improving access and affordability within the traditional insurance-based market.